Current Report Filing (8-k)
August 17 2020 - 04:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 8-K
___________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
Date of Report (Date of earliest event reported): August 17,
2020
CELLECTAR BIOSCIENCES,
INC.
(Exact name of registrant as specified in its charter)
Delaware
|
1-36598
|
04-3321804
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
100 Campus Drive, Florham Park, New Jersey 07932
(Address of principal executive offices, and zip code)
(608) 441-8120
(Registrant's telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
¨ |
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each
class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
Common stock, par value $0.00001
Warrant to purchase common stock, expiring April 20, 2021
|
|
CLRB
CLRBZ
|
|
NASDAQ Capital Market
NASDAQ Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
¨
ITEM 7.01 REGULATION FD
DISCLOSURE
On August 17, 2020, we issued a press release announcing that
Jarrod Longcor, our chief business officer, presented a poster at
the American Association of Cancer Research (AACR) VIRTUAL MEETING:
ADVANCES IN MALIGNANT LYMPHOMA being held August 17-19, 2020. A
copy of the press release is furnished as Exhibit 99.1 and is
incorporated by reference herein.
ITEM 9.01 FINANCIAL
STATEMENTS AND EXHIBITS
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Dated: August 17,
2020 |
CELLECTAR
BIOSCIENCES, INC. |
|
|
|
|
|
|
|
By: |
/s/ Dov Elefant |
|
|
Name: Dov
Elefant |
|
|
Title: Chief Financial
Officer |